Trial · NCT02463799
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation | Sipuleucel-T and Radium 223 Combination | 7.0 | Inter-Quartile Range 4.12 to 20.2 | fold change | |
| Immune Responses to Treatment With Sipuleucel-T (With or Without Radium-223) Measured by Peripheral PA2024 T-cell Proliferation | Sipuleucel-T Alone | 22.4 | Inter-Quartile Range 17.2 to 31.4 | fold change | |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T and Radium 223 Combination | Baseline | 1.7 | Inter-Quartile Range 1.0 to 2.2 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T Alone | Baseline | 1.4 | Inter-Quartile Range 1.2 to 1.5 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T and Radium 223 Combination | Week 6 | 25.7 | Inter-Quartile Range 4.4 to 37.0 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T Alone | Week 6 | 49.8 | Inter-Quartile Range 30.5 to 44.5 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T and Radium 223 Combination | Week 10 | 27.8 | Inter-Quartile Range 8.6 to 34.2 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T Alone | Week 10 | 42.0 | Inter-Quartile Range 26.3 to 56.0 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T and Radium 223 Combination | Week 14 | 23.0 | Inter-Quartile Range 7.0 to 21.8 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T Alone | Week 14 | 42.2 | Inter-Quartile Range 32.1 to 56.1 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T and Radium 223 Combination | Week 26 | 27.2 | Inter-Quartile Range 12.2 to 26.4 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T Alone | Week 26 | 25.6 | Inter-Quartile Range 15.4 to 36.6 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T and Radium 223 Combination | Week 39 | 20.7 | Inter-Quartile Range 5.4 to 22.3 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T Alone | Week 39 | 25.3 | Inter-Quartile Range 25.3 to 25.3 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T and Radium 223 Combination | Week 52 | 16.5 | Inter-Quartile Range 4.4 to 23.3 | Stimulation Index |
| Peripheral PA2024 Specific T-cell Proliferation as Measured by Stimulation Index Over Time | Sipuleucel-T Alone | Week 52 | 11.8 | Inter-Quartile Range 11.8 to 11.8 | Stimulation Index |
| Time to Radiographic or Clinical Progression | Sipuleucel-T and Radium 223 Combination | 38.7 | 95% Confidence Interval 18.9 to NA | WEEKS | |
| Time to Radiographic or Clinical Progression | Sipuleucel-T Alone | 11.9 | 95% Confidence Interval 8.0 to 15.0 | WEEKS | |
| PSA50 Response (at Least a 50% Decline in PSA) | Sipuleucel-T and Radium 223 Combination | 0 | Participants | ||
| PSA50 Response (at Least a 50% Decline in PSA) | Sipuleucel-T Alone | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02463799/results